肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.
我们描述了一例继发性外周 T 细胞淋巴瘤（PTCL），其来源于一名携带致病性胚系 BLM p.L107Ffs*36 变异的复发或难治性 B 细胞淋巴瘤患者输注的 CD19/CD22-4-1BB-CD3-lenti 双特异性嵌合抗原受体（CAR）-T 细胞。
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target
基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.
CD19 CAR-T 疗法在复发/难治性非霍奇金淋巴瘤（NHL）中已取得显著缓解。
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
非霍奇金淋巴瘤（NHL）是血液系统常见的恶性肿瘤，传统治疗对复发/难治性NHL（R/R NHL）患者疗效有限，尤其是弥漫大B细胞淋巴瘤（DLBCL）患者。
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
中位年龄为 59 岁（范围 27-83），46/52 例为 III/IV 期疾病，中位随访时间为 21.6 个月。
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
识别 CD19 的 CAR T 细胞可有效治疗复发/难治性 B-ALL 和 DLBCL。
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies.
工程化T细胞疗法，如CAR-T细胞和TCR-T细胞，在以往无法治愈的疾病中产生了令人瞩目的患者反应。
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational s
CD19/CD22 BS Loop CAR-T 细胞疗法表现出强效的抗淋巴瘤活性，同时解决了设计对两种抗原具有同等效力的 CAR-T 细胞所面临的挑战。
Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.
可从全血中成功制备具有治疗相关剂量的 CD19/CD22 CAR-T 细胞。
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
几种靶向CD19的CAR-T 细胞（CART19）产品已被批准用于治疗复发/难治性非霍奇金淋巴瘤（NHL）和急性淋巴细胞白血病（ALL）患者。
MEMBER ACCOUNT
登录成功会直接打开下一页。
